Gidi Benyamini

Chief Scientific Officer at Notal Vision

Gidi Benyamini has a diverse work experience spanning over a period of several years. Gidi started their career at Scitex Corporation as the Director of Operation - Input Systems from 1992 to 1999. Following that, they joined Lasercomm as the VP of Manufacturing and Engineering from 1999 to 2002. Currently, they are serving as the CTO and Director of the Israel Innovation Center at Notal Vision since January 2019. Additionally, they held the position of COO at Notal Vision from October 2002 onwards.

Gidi Benyamini completed their Bachelor of Arts (BA) degree in Mechanical Engineering at Tel Aviv University from 1985 to 1989. Later, they pursued a Master of Business Administration (MBA) from Fairleigh Dickinson University from 1993 to 1995.

Links


Org chart


Teams


Offices

This person is not in any offices


Notal Vision

Notal Vision is a patient-centric ophthalmic remote monitoring services provider extending retinal disease monitoring from the clinic to the home, providing physicians with remote monitoring services to support their patient care between office visits. With a proven approach to home-based, self-operated diagnostics, AI-enabled data analysis, and patient engagement, we help preserve patients’ vision. The Notal Vision Monitoring Center is a remote, Medicare credentialed ophthalmic provider and the epicenter of patient engagement. Led by practicing ophthalmologists and supported by certified ophthalmic professionals, the Monitoring Center offers a comprehensive nationwide age-related macular degeneration (AMD) home monitoring service for referred patients. The ForeseeHome® AMD Monitoring Program helps physicians detect the conversion to wet AMD early, leading to earlier treatment intervention and better visual outcomes. Our Home OCT pipeline technology will provide patient-initiated retinal OCT scans to support the management of patients with neovascular retinal diseases, complementing existing in-office imaging and standard of care treatments as well as emerging longer acting drugs and drug delivery systems.


Industries

Employees

51-200

Links